NOT FOR DISTRIBUTION
Header cover image

Market Cap

€228.4m

Last Updated

2021/04/14 20:01 UTC

Data Sources

Company Financials +

Executive Summary

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. More Details


Snowflake Analysis

Flawless balance sheet and undervalued.


Similar Companies

Share Price & News

How has Co-Diagnostics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: C97 is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: C97's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.


Market Performance


7 Day Return

-0.8%

C97

2.9%

DE Medical Equipment

0.2%

DE Market


1 Year Return

-14.3%

C97

41.5%

DE Medical Equipment

42.4%

DE Market

Return vs Industry: C97 underperformed the German Medical Equipment industry which returned 41.5% over the past year.

Return vs Market: C97 underperformed the German Market which returned 42.4% over the past year.


Shareholder returns

C97IndustryMarket
7 Day-0.8%2.9%0.2%
30 Day-29.6%7.6%5.1%
90 Day-6.7%13.0%9.6%
1 Year-14.3%-14.3%43.2%41.5%47.0%42.4%
3 Yearn/a95.4%87.0%23.5%12.8%
5 Yearn/a338.7%322.5%51.0%29.5%

Long-Term Price Volatility Vs. Market

How volatile is Co-Diagnostics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Co-Diagnostics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: C97 (€7.48) is trading below our estimate of fair value (€161.23)

Significantly Below Fair Value: C97 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: C97 is good value based on its PE Ratio (5.5x) compared to the DE Medical Equipment industry average (46.3x).

PE vs Market: C97 is good value based on its PE Ratio (5.5x) compared to the German market (28.2x).


Price to Earnings Growth Ratio

PEG Ratio: C97's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: C97 is good value based on its PB Ratio (3.8x) compared to the DE Medical Equipment industry average (7.9x).


Future Growth

How is Co-Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-43.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: C97's earnings are forecast to decline over the next 3 years (-43.6% per year).

Earnings vs Market: C97's earnings are forecast to decline over the next 3 years (-43.6% per year).

High Growth Earnings: C97's earnings are forecast to decline over the next 3 years.

Revenue vs Market: C97's revenue is expected to decline over the next 3 years (-1.3% per year).

High Growth Revenue: C97's revenue is forecast to decline over the next 3 years (-1.3% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if C97's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Co-Diagnostics performed over the past 5 years?

53.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: C97 has a high level of non-cash earnings.

Growing Profit Margin: C97 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: C97 has become profitable over the past 5 years, growing earnings by 53% per year.

Accelerating Growth: C97 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: C97 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (44.3%).


Return on Equity

High ROE: C97's Return on Equity (63.7%) is considered outstanding.


Financial Health

How is Co-Diagnostics's financial position?


Financial Position Analysis

Short Term Liabilities: C97's short term assets ($68.4M) exceed its short term liabilities ($4.5M).

Long Term Liabilities: C97's short term assets ($68.4M) exceed its long term liabilities ($30.0K).


Debt to Equity History and Analysis

Debt Level: C97 is debt free.

Reducing Debt: C97 currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: C97 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: C97 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Co-Diagnostics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate C97's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate C97's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if C97's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if C97's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of C97's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average board tenure


CEO

Dwight Egan (67 yo)

no data

Tenure

US$1,463,625

Compensation

Mr. Dwight H. Egan serves as the Chairman, Chief Executive Officer and President at Co-Diagnostics, Inc. and has been its Director since April 2013. Mr. Egan has been engaged in private investment business...


CEO Compensation Analysis

Compensation vs Market: Dwight's total compensation ($USD1.46M) is above average for companies of similar size in the German market ($USD564.45K).

Compensation vs Earnings: Dwight's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: C97's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: C97 insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.5%.


Top Shareholders

Company Information

Co-Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Co-Diagnostics, Inc.
  • Ticker: C97
  • Exchange: MUN
  • Founded: 2013
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$273.471m
  • Listing Market Cap: US$228.403m
  • Shares outstanding: 28.67m
  • Website: https://www.codiagnostics.com

Number of Employees


Location

  • Co-Diagnostics, Inc.
  • 2401 South Foothill Drive
  • Suite D
  • Salt Lake City
  • Utah
  • 84109
  • United States

Listings


Biography

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules. It...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/14 20:01
End of Day Share Price2021/04/14 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.